Johnson & Johnson patented a form of the psychedelic with less research and a ridiculous price tag. In a popular and public move, the United States’ Federal Drug Administration recently approved intranasal esketamine, one of the components of the psychedelic ketamine, for treatment-resistant depression. The nasal spray costs nearly $900 per dose—or roughly $7,000 for the first month […]
Esketamine
Esketamine Nasal Spray from Lori Calabrese, MD | The Ketamine Blog
We provide these articles about esketamine nasal spray, known by the brand name Spravato, to inform… and explain the similarities and differences between esketamine and ketamine, the compound esketamine was derived from.
Racemic Ketamine and Its Twin Molecules
As a compound made of two mirror-image molecules, racemic ketamine performs with extraordinary and robust antidepressant strength. We call those mirror-image molecules enantiomers. So, the word “racemic” simply means a compound made of right-handed and left-handed molecules.
You probably notice that identical twins look not so much exactly the same, but rather, they look like mirror images of each other. This phenomenon occurs all through nature. And you see it on the cell level, too.
The fact that these molecules are mirror images of each other doesn’t mean they’re identical. They’re similar…and have similar properties. Sometimes you see this with identical twins. For instance, one twin shows empathy, compassion, and introversion, while the other fills a room with laughter and friendliness.
In the same way, these molecules act differently also, with one showing stronger properties of one kind and the other showing stronger properties of another. It’s the synergy between the two that creates the characteristics of the full racemic compound.
The ketamine compound dynamically illustrates this. Each enantiomer behaves in some ways like the other, and behaves differently from the other in other ways.
We recognize the left enantiomer molecule s-ketamine…”s” being an abbreviation for the latin term for “left.” We recognize the right one r-ketamine, which is much easier to remember, right? So, with this in mind, they created a name that uses the “s” or the “r” phonetically. So these enantiomers enjoy the nicknames of esketamine and arketamine. Clever-ish…maybe?
Creating a NEW Medicine with an Old Molecule
Researchers hoped that by separating the left mirror-image molecule from the right-side one, they could produce an antidepressant with fewer side effects and less addiction risk. They knew they needed an entirely new compound. Because they needed the financial benefits of a patent to pay for the extensive research and testing that would be required to receive FDA approval.
It turned out that their new medicine required the aide of a newly initiated anti-depressant to perform as an antidepressant effectively. But with that antidepressant added, it showed some promising ability for erasing suicidal thinking and lifting depression.
Unfortunately, life in the laboratory behaves a lot like life everywhere else. It can be unpredictable. During the trials required for FDA approved, esketamine performed like a champ in some trials, and failed rather miserably in others.
At a time when the suicide rate rises higher and higher, psychiatrists need medicines that erase suicidal thinking. As a result, the FDA approved this new medicine along with its specially designed spray in March 2019. They took precautions, however.
They imposed safeguards. One such safeguard required that doses be restricted to administration in the office under medical supervision. Another one required that the doctor hold the patient for observation in the office for 2 hours after each dose, in case of side effects.
A Ketamine-Derived Medicine Covered by Insurance?
Janssen, a company owned by Johnson&Johnson which developed this medicine, promises that esketamine nasal spray will be covered by insurance. So, we’re waiting to hear what the coverage will be.
Will Spravato replace IV ketamine treatment? Probably not.
While esketamine may not be as effective as ketamine and is more expensive to administer. Does it have a place in treatment of depression and suicidal thinking? We certainly hope so. The fact that insurance companies plan to provide coverage for it will hopefully make it available to patients who find IV ketamine treatment is out of reach financially.
Because of the way the media promoted Spravato (esketamine), most people think that ketamine nasal spray was approved by the FDA. Esketamine isn’t ketamine, but it IS derived from ketamine. It performs with some of ketamine’s traits, but not others.
At Innovative Psychiatry, we embrace treatments that may help. And we hope esketamine will help some who haven’t been helped by traditional antidepressants or anxiety medicines. As you read these articles about esketamine nasal spray, remember this is a new medication and we’ll know more as we use it to treat the conditions it’s been developed to relieve.
Revitalize Psychiatry: Disrupt – Include – Engage – Innovate !! – The APA 2019 Conference
I just returned from the American Psychiatric Association’s 2019 Conference in San Francisco. This is the 175th Anniversary of the APA, and look how far we’ve come. The theme this year was: Revitalize Psychiatry – Disrupt – Include – Engage – Innovate. and it certainly provided fodder toward those goals. It was an informative and […]
The Oddities, Charm, and Suffering of Bipolar Disorder
“Though I am often in the depth of misery, there is still calmness, pure harmony, and music inside me.” —Vincent Van Gogh May is Mental Health Awareness Month, and I’ve been thinking about how to disrupt the stigma of “mental illness.” It’s a term I don’t like – but it’s still used throughout the world, […]
When You’re Touched by the Tragedy of Suicide
We celebrated Mother’s Day yesterday. What was it like for you? We truly hope you enjoyed a day of love and hugs as you celebrated with your children. But if you’re a mom who has lost a child, and especially if you’ve lost a child by suicide, this is a day that reminds you of […]
Misinformation about Esketamine (Spravato) and IV Ketamine
They’re different, but each can bring relief to those who suffer. As word gets out that esketamine intranasal spray has been approved by the FDA, the internet is rippling with articles, posts, interviews, newsclips and press releases about ketamine — IV ketamine, esketamine, and ketamine nasal spray. And — online forums and meeting places are […]
Ketamine: Dissociation Quality Determines Remission
Transformative remission is inextricably linked to the quality, depth, and degree of dissociation during ketamine infusions. Christopher trudged through the day, listless. He felt dead inside. Just couldn’t work up a care about what happened at the job interview. But practicality — the bills were piling up — drove him to go anyway. He did […]
Esketamine FDA Approval Marks a New Era in Psychiatric Medicine
Have you heard? In the “ketamine for depression” world we’re all a-buzz. Esketamine nasal spray’s been added to our arsenal to fight refractory depression. This is the first psychiatric medicine of its kind to win FDA approval. A medicine developed in a new brand new direction — glutamate modulation — to stimulate production of BDNF […]
Ketamine Treatment and the Science of Joy
Do you trudge or dance ? Trudging through life isn’t reserved for only the sick, the suffering, and the poverty-stricken. On some level, trudging is part of the routine of daily living for many. Certainly, it isn’t the sentence for every human. But why? Could the reason be hidden in the science of joy…? Or […]
Advances in Psychiatric Treatment: 2018 in Review
Happy New Year!! The big silver ball falls tonight to celebrate the birth of 2019. Let’s celebrate the unprecedented, transforming, and ever-accelerating advances in psychiatric treatment this year and the neuroscience that backs it up. Celebrate is the word. Because we’re so grateful to the courageous researchers around the beginning of the 21st century who […]
2018 Innovative Psychiatry: Ketamine Developments
What a year it’s been!! As this busy year creeps toward its end, it’s fun to look back on all we’ve accomplished in our hard work to help find more effective treatment for those who suffer with symptoms that don’t respond to traditional treatment. Since the early beginnings in my work as a psychiatrist, I’ve […]